Skip to content

Ardelyx ARDX Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
372.8M+0.9%
AbbVie logo
AbbVieABBV
1.8B+0.1%
XER
Xeris Biopharma Holdings, Inc.XERS
177.6M+16.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
31.5M+17.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
103.4M+0.9%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's shares (diluted)?
Ardelyx (ARDX) reported shares (diluted) of 245.9M in Q1 2026.
How has Ardelyx's shares (diluted) changed year-over-year?
Ardelyx's shares (diluted) increased by 3.0% year-over-year, from 238.6M to 245.9M.
What is the long-term trend for Ardelyx's shares (diluted)?
Over 4 years (2021 to 2025), Ardelyx's shares (diluted) has grown at a 24.1% compound annual growth rate (CAGR), from 405.6M to 961.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.